As COVID-19 vaccine sales collapse, a new study raises fresh concerns about the biological mechanism behind post-vaccine myocarditis. Del breaks down how the immune-driven T-cell response may be attacking healthy heart tissue—and why many say placebo-controlled trials should have been required before the mass rollout.